Thrombolytic and antiplatelet therapy in peripheral vascular disease with use of reteplase and/or abciximab - The SCVIR Consultants' Conference; May 22, 2000; Orlando, FL

被引：18

作者：

Benenati, J

Shlansky-Goldberg, R

Meglin, A

Seidl, E

机构：

[1] Miami Cardiac & Vasc Inst, Peripheral Vasc Lab, Miami, FL 33176 USA

[2] Univ Penn, Div Intervent Radiol, Hlth Syst, Philadelphia, PA 19104 USA

[3] Allegheny Gen Hosp, Pittsburgh, PA 15212 USA

[4] New Hanover Med Ctr, Delaney Radiologists, Dept Radiol, Wilmington, NC USA

来源：

JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY | 2001年 / 12卷 / 07期

关键词：

abciximab; reteplase; thrombolysis; tissue-type plasminogen activator;

D O I：

10.1016/S1051-0443(07)61503-6

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

[No abstract available]

引用

页码：795 / 805

页数：11

共 57 条

[1]

Adams HP, 2000, STROKE, V31, P601

[2]

*AM SOC HLTH SYST, 2000, AM J HEALTH-SYST PH, V57, P150

[3]

[Anonymous], J VASC MED BIOL

[4] Abciximab facilitates the rate and extent of thrombolysis - Results of the thrombolysis in myocardial infarction (TIMI) 14 trial [J].

Antman, EM ;

Giugliano, RP ;

Gibson, CM ;

McCabe, CH ;

Coussement, P ;

Kleiman, NS ;

Vahanian, A ;

Adgey, AAJ ;

Menown, I ;

Rupprecht, HJ ;

Van der Wieken, R ;

Ducas, J ;

Scherer, J ;

Anderson, K ;

Van de Werf, F ;

Braunwald, E .

CIRCULATION, 1999, 99 (21) :2720-2732

[5]

Berkompas DC, 1998, CATHETER CARDIO DIAG, V45, P272, DOI 10.1002/(SICI)1097-0304(199811)45:3<272::AID-CCD12>3.0.CO

[6]

2-W

[7] Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (Recombinant plasminogen activator) and front-loaded, accelerated alteplase (Recombinant tissue plasminogen activator) in patients with acute myocardial infarction [J].

Bode, C ;

Smalling, RW ;

Berg, G ;

Burnett, C ;

Lorch, G ;

Kalbfleisch, JM ;

Chernoff, R ;

Christie, LG ;

Feldman, RL ;

Seals, AA ;

Weaver, WD .

CIRCULATION, 1996, 94 (05) :891-898

[8] Augmented experimental pulse-spray thrombolysis with tissue plasminogen activator, enabling dose reduction by one or more orders of magnitude [J].

Bookstein, JJ ;

Bookstein, FL .

JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2000, 11 (03) :299-303

[9] USE OF A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY [J].

CALIFF, RM ;

SHADOFF, N ;

VALETT, N ;

BATES, E ;

GALEANA, A ;

KNOPF, W ;

SHAFTEL, J ;

BENDER, MJ ;

AVERSANO, T ;

RAQUENO, J ;

GURBEL, P ;

COWFER, J ;

COHEN, M ;

CROSS, P ;

BITTL, J ;

EDDINGS, K ;

TAYLOR, M ;

DEROSA, K ;

HATTEL, L ;

COOPER, L ;

ESHELMAN, B ;

FINTEL, D ;

NIEMYSKI, P ;

KLEIN, L ;

KENNEDY, H ;

THORNTON, T ;

KEREIAKES, D ;

MARTIN, L ;

ANDERSON, L ;

HIGBY, N ;

ELLIS, S ;

BREZINA, K ;

GEORGE, B ;

CHAPEKIS, A ;

SMITH, D ;

ANWAR, A ;

GERBER, TL ;

PRITCHARD, GL ;

MYLER, R ;

SHAW, R ;

MURPHY, M ;

WARD, K ;

MADIGAN, NP ;

BLANKENSHIP, J ;

HALBERT, M ;

FLANAGAN, C ;

TANNENBAUM, M ;

POLICH, M ;

STEVENSON, C ;

TCHENG, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (14) :956-961

[10] Overcoming thrombolytic resistance - Rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction [J].

Cannon, CP .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 34 (05) :1395-1402

← 1 2 3 4 5 6 →